Celecoxib
A selective COX-2 inhibitor that reduces prostaglandin synthesis to relieve pain, inflammation, and fever, while causing fewer gastrointestinal side effects than non-selective NSAIDs due to its sparing of COX-1. It is approved for arthritis, acute pain, primary dysmenorrhea, and familial adenomatous polyposis. Like all COX-2 inhibitors, it carries a cardiovascular risk that must be weighed against its benefits.
Moleküler Ağırlık
381,3730 g/mol
LogP
3,40
TPSA
86,40 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
İlaç Sınıfları
Etki Mekanizması
Selective COX-2 inhibitor.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selective COX-2 inhibitor.
2D Yapı
Cite this structure
Embed this structure
SMILES
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
InChI
InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
Molecular Formula
C17H14F3N3O2S
HBD / HBA
1 / 7
Döndürülebilir Bağlar
3
Ağır Atomlar
26
Celecoxib, a selective COX-2 inhibitor, can inhibit CYP2C9-mediated warfarin metabolism and may increase GI bleeding risk, though platelet function is less impaired than with non-selective NSAIDs.
Celecoxib, a selective COX-2 inhibitor, attenuates the antihypertensive effect of lisinopril and increases the risk of renal impairment.
Celecoxib may increase methotrexate exposure by reducing its renal clearance, raising the risk of toxicity in patients on MTX-based regimens.
Combining aspirin with celecoxib provides no additional gastroprotective benefit over aspirin alone and may negate the GI advantage of celecoxib, increasing the risk of mucosal injury.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A selective COX-2 inhibitor that reduces prostaglandin synthesis to relieve pain, inflammation, and fever, while causing fewer gastrointestinal side effects than non-selective NSAIDs due to its sparing of COX-1. It is approved for arthritis, acute pain, primary dysmenorrhea, and familial adenomatous polyposis. Like all COX-2 inhibitors, it carries a cardiovascular risk that must be weighed against its benefits.
Selective COX-2 inhibitor.
Key pharmacokinetic parameters for Celecoxib: Half-life: 11 hours.
Yes, Celecoxib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL118. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2662. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="celecoxib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/celecoxib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/celecoxib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/celecoxib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="celecoxib"></drugfyi-drug>